Evidence map›Paper›PMID 28749098›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2017

Association of XRCC2 rs3218536 Polymorphism with Susceptibility of Breast and Ovarian Cancer: A Systematic Review and Meta-Analysis

Mahdieh Kamali, Sedigheh Hamadani, Hossein Neamatzadeh, Mahta Mazaheri, Masoud Zare Shehneh, Mitra Modaress Gilani, Fatemeh Haghighi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 7 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 7 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mahdieh KamaliDepartment of Perinatology, School of Medicine, Tehran University Medical of Sciences, Tehran, Iran.
Sedigheh Hamadani
Hossein Neamatzadeh
Mahta Mazaheri
Masoud Zare Shehneh
Mitra Modaress Gilani
Fatemeh Haghighi
Shahid Sadoughi University of Medical Sciences and Health Services · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Previous studies have investigated the association of X-Ray Repair Cross-Complementing Group 2 (XRCC2) rs3218536 polymorphism with breast and ovarian cancer. However, this association remains conflicting. Therefore, we have performed the current systematic review and meta-analysis to clarify the association between XRCC2 rs3218536 polymorphism with risk of breast and ovarian cancer. Methods: We conducted a search in PubMed, Google Scholar and ISI Web of Science to select relevant studies on the association of XRCC2 rs3218536 polymorphism with breast and ovarian cancer susceptibility. We calculated the odds ratios (OR) and 95% confidence intervals (CI) for five genetic contrasts. In addition, a stratified analysis was conducted cancer type, ethnicity and HWE status. Results: A total of 17 studies with 5694 cases and 6450 controls for breast cancer and nine case-control studies with 4464 cases and 6353 controls for ovarian cancer were identified for the analysis of the association with XRCC2 rs3218536 polymorphism. The pooled ORs revealed that XRCC2 rs3218536 polymorphism was associated with breast cancer under the heterozygote contrast (AG vs. GG: OR = 0.929, 95% CI = 0.873-0.987, p=0.018) and ovarian cancer under dominant contrast (AA+AG vs. GG: OR = 0.725, 95% CI = 0.537-0.979, p=0.036) in the overall population. The stratified analysis indicated a significant association of XRCC2 rs3218536 polymorphism with breast and ovarian cancer risk among Caucasians. Conclusion: Inconsistent with previous meta-analysis, this meta-analysis shows that the XRCC2 rs3218536 polymorphism was associated with breast and ovarian cancer risk in overall population, especially among Caucasians.

Indexed as

Breast cancermeta-analysisovarian cancerpolymorphismXRCC2 rs3218536

Identifiers

PMID28749098
PMCPMC5648374
OpenAlexW2735470644

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.